Noninvasive quantitation of human liver steatosis using magnetic resonance and bioassay methods

被引:0
作者
Gaspard d’Assignies
Martin Ruel
Abdesslem Khiat
Luigi Lepanto
Miguel Chagnon
Claude Kauffmann
An Tang
Louis Gaboury
Yvan Boulanger
机构
[1] Centre hospitalier de l’Université de Montréal (CHUM),Département de radiologie
[2] Centre hospitalier de l’Université de Montréal (CHUM),Département d’anatomo
[3] Université de Montréal (UDEM),pathologie
[4] Hôpital Saint-Luc du CHUM,Département de mathématiques et de statistique
来源
European Radiology | 2009年 / 19卷
关键词
Liver steatosis; MRI; Magnetic resonance spectroscopy; Histopathology; Fat quantitation;
D O I
暂无
中图分类号
学科分类号
摘要
The purpose was to evaluate the ability of three magnetic resonance (MR) techniques to detect liver steatosis and to determine which noninvasive technique (MR, bioassays) or combination of techniques is optimal for the quantification of hepatic fat using histopathology as a reference. Twenty patients with histopathologically proven steatosis and 24 control subjects underwent single-voxel proton MR spectroscopy (MRS; 3 voxels), dual-echo in phase/out of phase MR imaging (DEI) and diffusion-weighted MR imaging (DWI) examinations of the liver. Blood or urine bioassays were also performed for steatosis patients. Both MRS and DEI data allowed to detect steatosis with a high sensitivity (0.95 for MRS; 1 for DEI) and specificity (1 for MRS; 0.875 for DEI) but not DWI. Strong correlations were found between fat fraction (FF) measured by MRS, DEI and histopathology segmentation as well as with low density lipoprotein (LDL) and cholesterol concentrations. A Bland-Altman analysis showed a good agreement between the FF measured by MRS and DEI. Partial correlation analyses failed to improve the correlation with segmentation FF when MRS or DEI data were combined with bioassay results. Therefore, FF from MRS or DEI appear to be the best parameters to both detect steatosis and accurately quantify fat liver noninvasively.
引用
收藏
页码:2033 / 2040
页数:7
相关论文
共 68 条
  • [1] Yan E(2007)Nonalcoholic fatty liver disease: pathogenesis, identification, progression, and management Nutr Rev 65 376-384
  • [2] Durazo F(2007)Pathology of nonalcoholic fatty liver disease Am J Clin Pathol 128 837-847
  • [3] Tong M(2007)Nonalcoholic fatty liver disease and cardiovascular disease risk Curr Diab Rep 7 181-187
  • [4] Yeh MM(2006)Nonalcoholic fatty liver disease: from steatosis to cirrhosis Hepatology 43 S99-S112
  • [5] Brunt EM(2002)Nonalcoholic fatty liver disease N Engl J Med 346 1221-1231
  • [6] Schindhelm RK(1999)Pain experienced during percutaneous liver biopsy Hepatology 30 1529-1530
  • [7] Diamant M(2003)Diagnosis of fatty liver disease: is biopsy necessary? Eur J Gastroenterol Hepatol 15 539-543
  • [8] Heine RJ(2005)Sampling variability of liver biopsy in nonalcoholic fatty liver disease Gastroenterology 128 1898-1906
  • [9] Farrell GC(2008)Nutrition and nonalcoholic fatty liver disease in children Curr Gastroenterol Rep 10 308-315
  • [10] Larter CZ(2004)Non-alcoholic steatohepatitis: review of a growing medical problem Eur J Intern Med 15 10-21